Kajian Teoretis Interaksi Antarmolekul pada Kompleks Inklusi Hidroksipropil-β-Siklodekstrin dan Hidroksiklorokuin

Authors

  • Atthar Luqman Ivansyah Program Studi Magister Sains Komputasi Fakultas Matematika dan Ilmu Pengetahuan Alam Institut Teknologi Bandung Kelompok Keahlian Kimia Analitik Departemen Kimia Institut Teknologi Bandung, Indonesia

DOI:

https://doi.org/10.15575/ak.v7i2.10113

Abstract

Di penghujung tahun 2019, terjadi wabah dengan gejala yang mirip dengan SARS di Republik Rakyat China yang disebabkan oleh virus SARS-CoV-2. Penyebaran virus yang masif, termasuk di Indonesia, menyebabkan WHO mengeluarkan status pandemi. Salah satu alternatif untuk mengurangi pasien COVID-19 adalah dengan menggunakan obat-obatan yang ada, hingga vaksin ditemukan dan siap digunakan. Saat ini, hidroksiklorokuin telah banyak diteliti sebagai kandidat obat anti COVID-19, yang kini telah memasuki tahap uji klinis. Namun kelarutan hidroksiklorokuin dalam air sangat kecil sehingga berdampak pada rendahnya ketersediaan hayati dalam tubuh manusia. Salah satu cara untuk meningkatkan kelarutan hidroksiklorokuin dalam air adalah melalui pembentukan kompleks inklusi yang stabil dengan hidroksipropil-β-siklodekstrin. Pada penelitian ini telah dilakukan studi komputasi dengan metode penambatan molekul dan metode kuantum semiempiris untuk mengetahui interaksi antara hidroksipropil-β-siklodekstrin dan hidroksiklorokuin. Hasil studi komputasi ini menunjukkan bahwa hidroksipropil-β-siklodekstrin dan hidroksiklorokuin membentuk kompleks inklusi yang stabil. Selain itu, kelarutan hidroksiklorokuin dalam larutan air dapat ditingkatkan dengan membentuk kompleks inklusi dengan hidroksipropil-β-siklodekstrin.

Kata Kunci: Hidroksipropil-β-Siklodekstrin; Hidroksiklorokuin; SARS-CoV-2; COVID-19; Kompleks Inklusi.

References

V. Sinha, R. Anitha, S. Ghosh, A. Nanda, and R. Kumria, "Complexation of celecoxib with β-cyclodextrin: Characterization of the interaction in solution and in solid state", Journal of Pharmaceutical Sciences, vol. 94, no. 3, pp. 676–687, 2005.

C. Anselmi, M. Centini, M. Ricci, A, Buonocore, P. Granata, et al., "Analytical characterization of a ferulic acid/γ-cyclodextrin inclusion complex", Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 4, pp. 875–881, 2006.

K.L. Yap, X. Liu, J.C. Thenmozhiyal, and P.C. Ho, "Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis", European Journal of Pharmaceutical Sciences, vol. 25, no. 1, pp. 49–56, 2005.

T. Irie and K. Uekama, "Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation", Journal of Pharmaceutical Sciences, vol. 86, no. 2, pp. 147–162, 1997.

M.E. Brewster and T. Loftsson, "Cyclodextrins as pharmaceutical solubilizers", Advanced Drug Delivery Reviews, vol. 59, no. 7, pp. 645–666, 2007.

R.L. Carrier, L.A. Miller, and I. Ahmed, "The utility of cyclodextrins for enhancing oral bioavailability", Journal of Controlled Release, vol. 123, no. 2, pp. 78–99, 2007.

K. Uekama, F. Hirayama, and T. Irie, “Cyclodextrin drug carrier systems,†Chem. Rev., vol. 98, no. 5, pp. 2045–2076, 1998.

F. Hirayama and K. Uekama, "Cyclodextrin-based controlled drug release system", Advanced Drug Delivery Reviews, vol. 36, no. 1, pp. 125–141, 1999.

M. Davis and M.E. Brewster, "Cyclodextrin-based pharmaceutics: Past, present and future", Nature Reviews Drug Discovery, vol. 3, no. 12, pp. 1023–1035, 2004.

T. Loftsson and M.E. Brewster, "Pharmaceutical applications of cyclodextrins: Effects on drug permeation through biological membranes", Journal of Pharmacy and Pharmacology, vol. 63, no. 9, pp. 1119–1135, 2011.

H. Matsuda and H. Arima, "Cyclodextrins in transdermal and rectal delivery", Advanced Drug Delivery Reviews, vol. 36, no. 1, pp. 81–99, 1999.

J. Szejtli, "Past, present, and future of cyclodextrin research", in Pure and Applied Chemistry, vol. 76, no. 10, pp. 1825–1845, 2004.

T. Loftsson and D. Duchêne, "Cyclodextrins and their pharmaceutical applications", International Journal of Pharmaceutics, vol. 329, no. 1–2, pp. 1–11, 2007.

V.J. Stella and R.A. Rajewski, "Cyclodextrins: Their future in drug formulation and delivery", Pharmaceutical Research, vol. 14, no. 5. pp. 556–567, 1997.

R. Cavalli, M. Donalisio, A. Civra, P. Ferruti, E. Ranucci, et al., "Enhanced antiviral activity of Acyclovir loaded into β-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles", Journal of Controlled Release, vol. 137, no. 2, pp. 116–122, 2009.

D. Lembo, S, Swaminathan, M. Donalosio, A. Civra, L. Pastero, et al., "Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent’s antiviral efficacy", International Journal of Pharmaceutics, vol. 443, no. 1–2, pp. 262–272, 2013.

S. Liang, M. Li, X. Yu, H. Jin, Y. Zhang, et al., "Synthesis and structure-activity relationship studies of water-soluble β-cyclodextrin-glycyrrhetinic acid conjugates as potential anti-influenza virus agents", European Journal of Medicinal Chemistry, vol. 166, pp. 328–338, 2019.

R.J. Glisoni, M.L. Cuestas, V.L. Mathet, J.R. Oubiña, A.G. Moglioni, and A. Sosnik, "Antiviral activity against the hepatitis C virus (HCV) of 1-indanone thiosemicarbazones and their inclusion complexes with hydroxypropyl-β-cyclodextrin", European journal of pharmaceutical sciences, vol. 47, no. 3, pp. 596–603, 2012.

S.C.J. Jorgensen, R. Kebriaei, and L.D. Dresser, "Remdesivir: Review of Pharmacology, Preâ€clinical Data, and Emerging Clinical Experience for COVIDâ€19", Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 40, no. 7, pp.24-29, 2020.

A.L. Ivansyah, "Investigasi Teoretis Interaksi Nonkovalen antara β-Siklodekstrin dan Hidroksiklorokuin," Akta Kimia Indonesia, vol. 5, no. 2, pp. 127-140, 2020.

S. Setiadji, C.D.D. Sundari, M.A. Ramdhani, A.B.K. Umam, and A.L. Ivansyah, "Theoretical Investigation of Inclusion Complex between Omeprazole Enantiomers and Carboxymethyl-β-Cyclodextrin", in IOP Conference Series: Materials Science and Engineering, vol. 288, no. 1, p. 012138, 2018.

A.L. Ivansyah, E.S. Nurhidayah, C.D.D. Sundari, M.A. Martoprawiro, and B. Buchari, “Computational study of inclusion complex between Omeprazole enantiomer and β-Cyclodextrin: NBO and RDG analysis", Journal of Physics: Conference Series, vol. 1402, no. 5, 2019.

S. Setiadji, C.D.D. Sundari, B.W. Nuryadin, H. Zayyinunnisya, R. Cahyandari, and A.L. Ivansyah, “Computational Study of Inclusion Complexes between Omeprazole Enantiomer with Hydroxypropyl-β-Cyclodextrin", Journal of Physics: Conference Series, vol. 1090, no. 1, 2018.

A.L. Ivansyah, M.A. Martoprawiro, and Buchari, “Computational modeling of inclusion complex of r/s-omeprazole with β-cyclodextrin using oniom2 methodâ€, in Journal of Physics: Conference Series, vol. 812, no. 1, 2017.

Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G.E. Scuseria, M.A. Robb et al., Gaussian, Inc., Wallingford CT, 2016.

E. Krieger and G. Vriend, "New ways to boost molecular dynamics simulations", Journal of Computational Chemistry, vol. 36, no. 13, pp. 996–1007, 2015.

M.D. Hanwell, D.E. Curtis, D.C. Lonie, T. Vandermeerschd, E. Zurek, and G.R. Hutchison, "Avogadro: An advanced semantic chemical editor, visualization, and analysis platform", Journal of Cheminformatics, vol. 4, no. 8, p. 17, 2012.

C. Betzel, W. Saenger, B.E. Hingerty, and G.M. Brown, "Circular and Flip-Flop Hydrogen Bonding in β-Cyclodextrin Undecahydrate: A Neutron Diffraction Study", Journal of the American Chemical Society, vol. 106, no. 24, pp. 7545–7557, 1984.

I. Andreadelis, M.V. Chatziathanasiadou, D. Ntountaniotis, G. Valsami, C. Papaemmanouil, et al., "Charting the structural and thermodynamic determinants in phenolic acid natural product – cyclodextrin encapsulations", Journal of Biomolecular Structure and Dynamics, pp. 1–17, 2020.

T.F. Kellici, M. Chatziathanasiadou, D. Diamantis, A.V. Chatzikonstantinou, I, Andreadelis, et al., "Mapping the interactions and bioactivity of quercetin—(2-hydroxypropyl)-β-cyclodextrin complex", International Journal of Pharmaceutics, vol. 511, no. 1, pp. 303–311, 2016.

D. Ntountaniotis, I. Andreadellis, T. Kellici, V. Karageorgos, G. Leonis, E. Christodoulou, et al., "Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism", Molecular Pharmaceutics, vol. 16, no. 3, pp. 1255–1271, 2019.

T.F. Kellici, D. Ntountaniotis, G. Leonis, M. Chatziathanasiadou, A.V. Chatzikonstantinou, et al., "Investigation of the interactions of silibinin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods", Molecular Pharmaceutics, vol. 12, no. 3, pp. 954–965, 2015.

G.G. Kordopati, T.V. Tselios, T. Kellici, F. Merzel, T. Mavromoustakos, et al., "A novel synthetic luteinizing hormone-releasing hormone (LHRH) analogue coupled with modified β-cyclodextrin: Insight into its intramolecular interactions", Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1850, no. 1, pp. 159–168, 2015.

G. Leonis, E. Christodoulou, D. Ntountaniotis, M. Chatziathanasiadou, T. Mavromoustakos, et al., “Antihypertensive activity and molecular interactions of irbesartan in complex with 2â€hydroxypropylâ€Î²â€cyclodextrin,†Chemical Biology and Drug Design, vol. 96, no. 1, pp. 668–683, 2020.

https://go.drugbank.com/drugs/DB01611. Accessed November 3, 2020.

Downloads

Published

2020-12-31

Issue

Vol. 7 No. 2 (2020): al Kimiya: Jurnal Ilmu Kimia dan Terapan

Section

Articles

Citation Check

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).